SEHK:1801Biotechs
Encouraging Early Data for IBI3016 Could Be a Game Changer for Innovent Biologics (SEHK:1801)
Innovent Biologics and SanegeneBio recently reported encouraging preliminary results from the first-in-human Phase 1 trial of IBI3016, an experimental siRNA therapy for hypertension, at the 2025 American Heart Association conference.
The study showed favorable safety, sustained AGT inhibition, and early antihypertensive effects, underscoring potential progress for innovative treatments in a large unmet market.
We'll look at how promising early clinical results with IBI3016 may reshape...